Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma

Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma. It is not known if there are differences in outcome between early versus delayed BEV treatment of recurrent glioblastoma. We examined the relationship between the time of starting BEV treatment and outcomes in pa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Neurooncol
Egile Nagusiak: Hamza, Mohamed A., Mandel, Jacob J., Conrad, Charles A., Gilbert, Mark R., Yung, W. K. Alfred, Puduvalli, Vinay K., DeGroot, John F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297475/
https://ncbi.nlm.nih.gov/pubmed/24803001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1460-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak